Abstract
An overview is presented of 23 trials of adjuvant chemotherapy in squamous cell carcinoma of the head and neck. These were reviewed from the point of view of design of the trial, analysis of survival, response rates, meta-analysis, site of failure, toxicity and cost. The minimal increase in survival that could be detected ranged from 11 to 51%, with a median of 25%. No trial was big enough to detect the likely increase of survival, which is 5%. Many trials excluded some eligible patients before randomisation, the proportion being 21% in those series with details. A further 9% of treated patients were excluded from analysis. A response rate in four induction studies of 47% equated with a 6% increase in cancer mortality. Meta-analysis showed an insignificant overall improvement in cancer mortality of 0.5%. Induction chemotherapy, synchronous chemotherapy and induction/maintenance chemotherapy did not affect cancer mortality whereas synchronous/maintenance therapy did. Cisplatinum, methotrexate, bleomycin, 5-FU and a variety of other regimens did not affect the death rate from cancer, but the combination of VBM significantly increased it. Neither single agent nor combination chemotherapy produced a significant reduction of cancer deaths. The rate of locoregional failure was significantly lower in the treated arms, whereas the metastatic rate was similar in both arms. Only three papers gave full details of toxicity with grading: these showed a high toxicity rate. The mortality rate from chemotherapy in nine series averaged 6.5%.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Trials Open Access 29 November 2014
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stell, P., Rawson, N. Adjuvant chemotherapy in head and neck cancer. Br J Cancer 61, 779–787 (1990). https://doi.org/10.1038/bjc.1990.175
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.175
This article is cited by
-
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Trials (2014)
-
Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?
Nature Clinical Practice Oncology (2005)
-
Lokale Chemotherapie oraler und oropharyngealer Plattenepithelkarzinome
Der Radiologe (2005)
-
Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer
Strahlentherapie und Onkologie (1998)
-
Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and-IV carcinomas of the head and neck
Strahlentherapie und Onkologie (1998)